500,000 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC purchased a new stake in Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 500,000 shares of the company’s stock, valued at approximately $30,285,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalent in the second quarter valued at approximately $42,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent in the 3rd quarter worth $53,000. Longfellow Investment Management Co. LLC increased its stake in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the period. GAMMA Investing LLC increased its position in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the period. Finally, Intact Investment Management Inc. purchased a new position in shares of Catalent during the 3rd quarter worth approximately $73,000.

Insider Transactions at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CTLT. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a research note on Thursday. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Catalent currently has a consensus rating of “Hold” and a consensus price target of $59.83.

Catalent Trading Up 0.3 %

CTLT opened at $59.10 on Friday. The firm’s 50 day moving average is $59.84 and its 200-day moving average is $58.18. Catalent, Inc. has a 52-week low of $36.74 and a 52-week high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $10.73 billion, a P/E ratio of -26.15, a P/E/G ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the business posted ($0.10) earnings per share. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. Analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.